Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Gilead

GileadGilead Sciences is a research-based biopharmaceutical company with interests in developing treatments in areas of unmet need for life threatening diseases. One of its primary focus areas is the development of antivirals for treatment of HIV/AIDS and chronic hepatitis.

 

Cham Herath 

Cham Herath is Medical Director at Gilead Sciences Ltd, UK and Ireland. He has over 10 years experience in the pharmaceutical industry and his clinical and research interests have focused predominantly on HIV antiretroviral clinical utilization with an interest in long term safety outcomes and toxicities of modern HIV therapies. 

In this section

The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.

Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.